Comparison of hepatic 2D sandwich cultures and 3d spheroids for long-term toxicity applications: A multicenter study

Toxicological Sciences

Volumn 162, Issue 2, 2018, Pages 655-666

  Bell, Catherine C ^a,b   Dankers, Anita C A ^c   Lauschke, Volker M ^a   Sison Young, Rowena ^d   Jenkins, Roz ^d   Rowe, Cliff ^d   Goldring, Chris E ^d   Park, Kevin ^d   Regan, Sophie L ^e   Walker, Tracy ^f   Schofield, Chris ^f   Baze, Audrey ^g,h   Foster, Alison J ^e   Williams, Dominic P ^e   van de Ven, Amy W M ^c   Jacobs, Frank ^c   van Houdt, Jos ^c   Lähteenmäki, Tuula ⁱ   Snoeys, Jan ^c   Juhila, Satu ⁱ   Richert, Lysiane ^h,j   Ingelman Sundberg, Magnus ^a   more..

^a KAROLINSKA INSTITUTE   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c JANSSEN RESEARCH FOUNDATION   (Belgium)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e ASTRAZENECA   (United Kingdom)

^f GLAXOSMITHKLINE   (United Kingdom)

^g KaLy Cell   (France)

^h UNIVERSITÉ DE STRASBOURG   (France)

ⁱ ORION CORPORATION   (Finland)

^j UNIVERSITÉ BOURGOGNE FRANCHE COMTÉ   (France)

more..

Author keywords

Cell culture; Cytotoxicity; Hepatocytes; Predictive toxicology

Indexed keywords

ACYL COENZYME A DESATURASE; ALCOHOL DEHYDROGENASE; APOLIPOPROTEIN B; APOLIPOPROTEIN C1; APOLIPOPROTEIN C2; APOLIPOPROTEIN E; BOSENTAN; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 4A11; DICLOFENAC; FIALURIDINE; GLUCURONOSYLTRANSFERASE 1A4; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE A2; GLUTATHIONE TRANSFERASE M1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 6; PARACETAMOL; PEROXIREDOXIN 1; PEROXIREDOXIN 6; PIOGLITAZONE; SERINE DEHYDRATASE; THREONINE AMMONIA LYASE; TROGLITAZONE; CYTOCHROME P450; DRUG;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CYTOTOXICITY; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LIVER CELL CULTURE; LONG TERM EXPOSURE; MALE; MIDDLE AGED; PHENOTYPE; TUMOR SPHEROID; UPREGULATION; BIOLOGICAL MODEL; CELL CULTURE; CELL SURVIVAL; COCULTURE; CRYOPRESERVATION; DOSE RESPONSE; DRUG EFFECT; LIVER CELL; METABOLISM; MULTICELLULAR SPHEROID; PATHOLOGY; PREDICTIVE VALUE; PRIMARY CELL CULTURE; PROCEDURES; STANDARDS; TIME FACTOR; TOXIC HEPATITIS; TOXICITY TESTING;

CELL SURVIVAL; CELLS, CULTURED; CHEMICAL AND DRUG INDUCED LIVER INJURY; COCULTURE TECHNIQUES; CRYOPRESERVATION; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPATOCYTES; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PREDICTIVE VALUE OF TESTS; PRIMARY CELL CULTURE; SPHEROIDS, CELLULAR; TIME FACTORS; TOXICITY TESTS;

EID: 85044844579     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfx289     Document Type: Article

References (45)

1. Bell, C.C., Hendriks, D.F.G., Moro, S.M.L., Ellis, E., Walsh, J., Renblom, A., Fredriksson Puigvert, L., Dankers, A.C.A., Jacobs, F., Snoeys, J., et al. (2016). Characterization of primary human hepatocyte spheroids as a model system for druginduced liver injury, liver function and disease. Scientific Reports 6, 25187.
2. Bell, C.C., Lauschke, V.M., Vorrink, S.U., Palmgren, H., Duffin, R., Andersson, T.B., and Ingelman-Sundberg, M. (2017). Transcriptional, functional, and mechanistic comparisons of stem cell-derived hepatocytes, HepaRG cells, and threedimensional human hepatocyte spheroids as predictive in vitro systems for drug-induced liver injury. Drug Metabolism and Disposition 45, 419-429.
3. Bellwon, P., Truisi, G.L., Bois, F.Y.,Wilmes, A., Schmidt, T., Savary, C.C., Parmentier, C., Hewitt, P.G., Schmal, O., Josse, R., et al. (2015). Kinetics and dynamics of cyclosporine A in three hepatic cell culture systems. Toxicology in Vitro 30, 62-78.
4. Bort, R., Macé , K., Boobis, A., Gómez-Lechón, M.J., Pfeifer, A., and Castell, J. (1999). Hepatic metabolism of diclofenac: Role of human CYP in the minor oxidative pathways. Biochemical Pharmacology 58, 787-796.
5. Bowsher, R.R., Compton, J.A., Kirkwood, J.A., Place, G.D., Jones, C.D., Mabry, T.E., Hyslop, D.L., Hatcher, B.L., and DeSante, K.A. (1994). Sensitive and specific radioimmunoassay for fialuridine: Initial assessment of pharmacokinetics after single oral doses to healthy volunteers. Antimicrobial Agents and Chemotherapy 38, 2134-2142.
6. Burbank, M.G., Burban, A., Sharanek, A., Weaver, R.J., Guguen-Guillouzo, C., and Guillouzo, A. (2016). Early alterations of bile canaliculi dynamics and the rho kinase/myosin light chain kinase pathway are characteristics of drug-induced intrahepatic cholestasis. Drug Metabolismand Disposition 44, 1780-1793.
7. Chatterjee, S., Richert, L., Augustijns, P., and Annaert, P. (2014). Hepatocyte-based in vitro model for assessment of druginduced cholestasis. Toxicology and Applied Pharmacology 274, 124-136.
8. Chen, L., Shu, Y., Liang, X., Chen, E.C., Yee, S.W., Zur, A.A., Li, S., Xu, L., Keshari, K.R., Lin, M.J., et al. (2014). OCT1 is a highcapacity thiamine transporter that regulates hepatic steatosis and is a target ofmetformin. Proceedings of the National Academy of Sciences of the United States of America 111, 9983-9988.
9. Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., and Pangalos, M.N. (2014). Lessons learned from the fate of AstraZeneca's drug pipeline: A fivedimensional framework. Nature Reviews Drug Discovery 13, 419-431.
10. De Bruyn, T., Chatterjee, S., Fattah, S., Keemink, J., Nicolaï, J., Augustijns, P., and Annaert, P. (2013). Sandwich-cultured hepatocytes: Utility for in vitro exploration of hepatobiliary drug disposition and drug-induced hepatotoxicity. Expert Opinion on Drug Metabolism & Toxicology 9, 589-616.
11. den Braver-Sewradj, S.P., den Braver, M.W., Vermeulen, N.P.E., Commandeur, J.N.M., Richert, L., and Vos, J.C. (2016). Interdonor variability of phase I/phase II metabolism of three reference drugs in cryopreserved primary human hepatocytes in suspension andmonolayer. Toxicology in Vitro 33, 71-79.
12. Dragovic, S., Vermeulen, N.P.E., Gerets, H.H., Hewitt, P.G., Ingelman-Sundberg, M., Park, B.K., Juhila, S., Snoeys, J., and Weaver, R.J. (2016). Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in man. Archives of Toxicology doi: 10.1007/s00204-016-18451, 1-25.
13. Evans, W.E., and Relling, M.V. (1999). Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 286, 487-491.
14. Ewart, L., Dehne, E.-M., Fabre, K., Gibbs, S., Hickman, J., Hornberg, E., Ingelman-Sundberg, M., Jang, K.-J., Jones, D.R., Lauschke, V.M., et al. (2018). Application of microphysiological systems to enhance safety assessment in drug discovery. Annual Review of Pharmacology and Toxicology 58.
15. Gómez-Lechón, M.J., Tolosa, L., Conde, I., and Donato, M.T. (2014). Competency of different cell models to predict human hepatotoxic drugs. Expert Opinion on Drug Metabolism & Toxicology 10, 1553-1568.
16. Gutierrez, M.M., Nicolas, L.B., Donazzolo, Y., and Dingemanse, J. (2013). Relative bioavailability of a newly developed pediatric formulation of bosentan vs. the adult formulation. International Journal of Clinical Pharmacology and Therapeutics 51, 529-536.
17. Heslop, J.A., Rowe, C., Walsh, J., Sison-Young, R., Jenkins, R., Kamalian, L., Kia, R., Hay, D., Jones, R.P., Malik, H.Z., et al. (2016). Mechanistic evaluation of primary human hepatocyte culture using global proteomic analysis reveals a selective dedifferentiation profile. Archives of Toxicology doi:10.1007/ s00204-016-1694-y, 1-14.
18. Laine, J.E., Auriola, S., Pasanen, M., and Juvonen, R.O. (2009). Acetaminophen bioactivation by human cytochrome P450 enzymes and animal microsomes. Xenobiotica 39, 11-21.
19. Lauschke, V.M., Hendriks, D.F.G., Bell, C.C., Andersson, T.B., and Ingelman-Sundberg, M. (2016a). Novel 3D culture systems for studies of human liver function and assessments of the hepatotoxicity of drugs and drug candidates. Chemical Research in Toxicology 29, 1936-1955.
20. Lauschke, V.M., and Ingelman-Sundberg, M. (2016). The importance of patient-specific factors for hepatic drug response and toxicity. International Journal of Molecular Sciences 17, 1714.
21. Lauschke, V.M., Vorrink, S.U., Moro, S.M.L., Rezayee, F., Nordling, A° ., Hendriks, D.F.G., Bell, C.C., Sison-Young, R., Park, B.K., Goldring, C.E., et al. (2016b). Massive rearrangements of cellular MicroRNA signatures are key drivers of hepatocyte dedifferentiation. Hepatology 64, 1743-1756.
22. Loi, C.M., Alvey, C.W., Vassos, A.B., Randinitis, E.J., Sedman, A.J., and Koup, J.R. (1999). Steady-state pharmacokinetics and dose proportionality of troglitazone and its metabolites. Journal of Clinical Pharmacology 39, 920-926.
23. Martignoni, M., Groothuis, G.M.M., and de Kanter, R. (2006). Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opinion on Drug Metabolism & Toxicology 2, 875-894.
24. Messner, S., Fredriksson, L., Lauschke, V.M., Roessger, K., Escher, C., Bober, M., Kelm, J.M., Ingelman-Sundberg, M., and Moritz, W. (2017). Transcriptomic, proteomic, and functional long-term characterization of multicellular threedimensional human liver microtissues. Applied in Vitro Toxicology aivt.2017.0022-12.
25. Olson,H., Betton,G., Robinson,D., Thomas,K., Monro, A.,Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000). Concordance of the toxicity of pharmaceuticals in humans and in animals. Regulatory Toxicology and Pharmacology 32, 56-67.
26. Onakpoya, I.J., Heneghan, C.J., and Aronson, J.K. (2016). Postmarketing withdrawal of 462 medicinal products because of adverse drug reactions: A systematic review of the world literature. BMC Medicine doi: 10.1186/s12916-016-0553-2, 1-11.
27. Oorts, M., Baze, A., Bachellier, P., Heyd, B., Zacharias, T., Annaert, P., and Richert, L. (2016). Drug-induced cholestasis risk assessment in sandwich-cultured human hepatocytes. Toxicology in Vitro 34, 179-186.
28. Park, B.K., Boobis, A., Clarke, S., Goldring, C.E.P., Jones, D., Kenna, J.G., Lambert, C., Laverty, H.G., Naisbitt, D.J., Nelson, S., et al. (2011). Managing the challenge of chemically reactive metabolites in drug development. Nature Reviews Drug Discovery 10, 292-306.
29. Parmentier, C., Couttet, P., Wolf, A., Zaccharias, T., Heyd, B., Bachellier, P., Uteng, M., and Richert, L. (2017). Evaluation of transcriptomic signature as a valuable tool to study druginduced cholestasis in primary human hepatocytes. Archives of Toxicology 91, 2879-2893.
30. Parmentier, C., Truisi, G.L., Moenks, K., Stanzel, S., Lukas, A., Kopp-Schneider, A., Alexandre, E., Hewitt, P.G., Mueller, S.O., and Richert, L. (2013). Transcriptomic hepatotoxicity signature of chlorpromazine after short-and long-term exposure in primary human sandwich cultures. Drug Metabolism and Disposition 41, 1835-1842.
31. Richert, L., Baze, A., Parmentier, C., Gerets, H.H.J., Sison-Young, R., Dorau, M., Lovatt, C., Czich, A., Goldring, C., Park, B.K., et al. (2016). Cytotoxicity evaluation using cryopreserved primary human hepatocytes in various culture formats. Toxicology Letters 258, 207-215.
32. Rowe, C., Gerrard, D.T., Jenkins, R., Berry, A., Durkin, K., Sundstrom, L., Goldring, C.E., Park, B.K., Kitteringham, N.R., Hanley, K.P., et al. (2013). Proteome-wide analyses of human hepatocytes during differentiation and dedifferentiation. Hepatology 58, 799-809.
33. Rowe, C., Goldring, C.E.P., Kitteringham, N.R., Jenkins, R.E., Lane, B.S., Sanderson, C., Elliott, V., Platt, V., Metcalfe, P., and Park, B.K. (2010). Network analysis of primary hepatocyte dedifferentiation using a shotgun proteomics approach. Journal of Proteome Research 9, 2658-2668.
34. Sevilla-Tirado, F.J., González-Vallejo, E.B., Leary, A.C., Breedt, H.J., Hyde, V.J., and Fernández-Hernando, N. (2003). Bioavailability of two new formulations of paracetamol, compared with three marketed formulations, in healthy volunteers. Methods and Findings in Experimental and Clinical Pharmacology 25, 531-535.
35. Sirenko, O., Hesley, J., Rusyn, I., and Cromwell, E.F. (2014). Highcontent assays for hepatotoxicity using induced pluripotent stem cell-derived cells. Assay and Drug Development Technologies 12, 43-54.
36. Sison-Young, R.L., Lauschke, V.M., Johann, E., Alexandre, E., Anthé rieu, S., Aerts, H., Gerets, H.H.J., Labbe, G., Hoeet, D., Dorau, M., et al. (2017). A multicenter assessment of singlecell models aligned to standard measures of cell health for prediction of acute hepatotoxicity. Archives of Toxicology 91, 1385-1400.
37. Soldatow, V.Y., LeCluyse, E.L., Griffith, L.G., and Rusyn, I. (2013). In vitromodels for liver toxicity testing. Toxicology Research 2, 23-39.
38. Thompson, R.A., Isin, E.M., Ogese, M.O., Mettetal, J.T., and Williams, D.P. (2016). Reactive metabolites: Current and emerging risk and hazard assessments. Chemical Research in Toxicology doi: 10.1021/acs.chemrestox.5b00410, acs.chemrestox. 5b00410-29.
39. Treyer, A., and Mü sch, A. (2013). Hepatocyte polarity. Comprehensive Physiology 3, 243-287.
40. Vorrink, S.U., Ullah, S., Schmidt, S., Nandania, J., Velagapudi, V., Beck, O., Ingelman-Sundberg, M., and Lauschke, V.M. (2017). Endogenous and xenobiotic metabolic stability of primary human hepatocytes in long-term 3D spheroid cultures revealed by a combination of targeted and untargeted metabolomics. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology doi: 10. 1096/fj.201601375R.
41. Wang, J., Duncan, D., Shi, Z., and Zhang, B. (2013). WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): Update 2013. Nucleic Acids Research 41, W77-W83.
42. Wong, H., Ozalp, Y., Lainesse, A., and Alpan, R.S. (2004). In vivo bioequivalence of oral antidiabetic agents: Pioglitazone tablets. Arzneimittel-Forschung 54, 618-624.
43. Yamamoto, Y., Yamazaki, H., Ikeda, T., Watanabe, T., Iwabuchi, H., Nakajima, M., and Yokoi, T. (2002). Formation of a novel quinone epoxide metabolite of troglitazone with cytotoxic to HepG2 cells. Drug Metabolism and Disposition: The Biological Fate of Chemicals 30, 155-160.
44. Yamazaki, H., Shibata, A., Suzuki, M., Nakajima, M., Shimada, N., Guengerich, F.P., and Yokoi, T. (1999). Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-4502C8 and P-450 3A4 in human liver microsomes. Drug Metabolism and Disposition: The Biological Fate of Chemicals 27, 1260-1266.
45. Zhou, Y., Ingelman-Sundberg, M., and Lauschke, V.M. (2017). Worldwide distribution of cytochrome P450 alleles: A metaanalysis of population-scale sequencing projects. Clinical Pharmacology & Therapeutics 102, 688-700.